Omrix Biopharmaceuticals Inc.

Ethicon, Gmbh

Opperbas Holding B.v.

Ethicon Endo-surgery, Inc.

Depuy Synthes Products, Inc.

Guangzhou Bioseal Biotech Co. Ltd

Guangzhou Science Co., Inc.

Omrix Biopharmaceutical, Inc.

Israel Nur

Liliana Bar

Roberto Meidler

Oleg Belyaev

Tamar Auerbach-Nevo

Ashley DeAnglis

Erez Ilan

Nadav Orr

Lior Weissman

Anne J Gorman

Moti Meron

Roee Atlas

Sivan Doron

Yair Pilpel

Yuri Zherdev

Eyal Sheetrit

Kfir Regev

Moshe Baru

Roni Mintz

Malkit Azachi

Guy Tomer

Nina Raver-Shapira

Itai Podoler

John V Hunt

Geoffrey C Hueil

John Mott Goodman

Sridevi N Dhanaraj

Anthony J Kihm

Ronen Eavri

Yehuda Shoenfeld

Charito S Buensuceso

Orgad Laub

Tamara Byk-Tennenbaum

Elena Grimberg

Miri Blank

Inbar Gahali-Sass

Edna Bechor

Dana Leitman

Frederick E Shelton, IV

Chester O Baxter, Iii

Taylor W Aronhalt

Matthew C Miller

Yechezkel Barenholz

Aron O Zingman

Yi-Lan Wang

Guanghui Zhang

Sanyog Manohar Pendharkar

Venkataramanan Mandakolathur Vasudevan

Dvorah Diminsky

Yonit Tiberman

Tali Negreanu-Gilboa

Lilianne K Bar

Joseph B Kraimer

Gregory J Fanuele

Greg J Fanuele

Venkataramanan Madakolathur Vasudevan

Hadas Alperin

Baochang An

Lilliana Bar

Caixia Jiang

Dana Sella

Lily Bar

Ashley De Anglis

Aner Tsuk

Oded Lieberman

Iv Frederick E Shelton

John Goodman

Lilian Menuha Bar

Roberto Medler

Charito Buensuceso

Meidler Roberto

Lillian Bar

Iii Chester O Baxter

Anne Jessica Gorman

Chester O Baxter

Provided is a method for purifying α-thrombin and for quantifying α-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified α-thrombin. The method can also be used for purification and/or quantification of β-thrombin.

Method for purifying and quantifying thrombin and its degradation polypeptides

The invention relates to a viral inactivated biological liquid or dry mixture and to its preparation. Principally, the invention relates, but is not limited, to a mixture derived from a platelet source.

Viral inactivated biological mixture

Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.

Thrombin solution and methods of use thereof

Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.

Stable pharmaceutical foam

Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.

Low concentrated protein compositions for preventing tissue adhesion

Provided are pharmaceutical compositions comprising an anion exchanger and a calcium salt; methods for inducing hemostasis at a site of bleeding by applying to the site of bleeding an effective amount of the compositions; and methods of preparation of the compositions.

Hemostatic composition comprising an anion exchanger and a calcium salt

Provided are methods and devices for dissolving solid protein compositions, such as solid compositions comprising fibrinogen, in an aqueous solvent. The methods comprise use of a closed container containing a volume of solid fibrinogen composition and a head space wherein the pressure within the headspace is sub-atmospheric. Aqueous solvent is introduced into the container while maintain the sub-atmospheric pressure, and subsequent to addition of the solvent, the size of the headspace is decreased to bring the pressure to atmospheric pressure. The devices are suitable for use in the disclosed method.

Method and device for fast dissolution of solid protein composition

Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 &#x3bc;M to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 &#x3bc;M to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.

High concentrated protein compositions for preventing tissue adhesion

Provided is a method for purifying &#x3b1;-thrombin and for quantifying &#x3b1;-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified &#x3b1;-thrombin. The method can also be used for purification and/or quantification of &#x3b2;-thrombin.

Provided herein is a plasma-supplemented fibrinogen and/or fibrin formulation, method for the preparation and use thereof.

Plasma-supplemented formulation

Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

One component fibrin glue comprising zymogens

Growing community of inventors

Moshav Timmorim, Israel

Israel Nur